Molnupiravir

Molnupiravir (development codes EIDD-2801 and MK-4482) is an investigational antiviral drug for oral administration for the treatment of influenza. It is an N4-hydroxycytidine-donating prodrug, a nucleoside derivative known to be mutagenic that acts against RNA viruses by introducing errors in RNA replication by the viral RNA-dependent RNA polymerase. It also has some activity against coronaviruses such as SARS-CoV, MERS-CoV and SARS-CoV-25, responsible for SARS, MERS and COVID-19 respectively. It was developed at Emory University in Atlanta, Georgia, before being acquired by Ridgeback Biotherapeutics in Miami, Florida, which has partnered with Merck & Co. for further development.

External Links

Coronavirus RNA Proofreading Molecular basis and therapeutic target

EIDD 2801

Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets

Source

enWiki(Miraheze)

  Interwiki via Wikidata